Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy.
Grunewald L, Andersch L, Helmsauer K, Schwiebert S, Klaus A, Henssen AG, Straka T, Lodrini M, Wicha SG, Fuchs S, Hertwig F, Westermann F, Vitali A, Caramel C, Büchel G, Eilers M, Astrahantseff K, Eggert A, Höpken UE, Schulte JH, Blankenstein T, Anders K, Künkele A.
Grunewald L, et al. Among authors: klaus a.
Pharmacol Res. 2025 Jan 17:107608. doi: 10.1016/j.phrs.2025.107608. Online ahead of print.
Pharmacol Res. 2025.
PMID: 39828101
Free article.